Medicine
Elahere 100 mg/20 mL injection
Elahere 100 mg/20 mL injection is a prescription medicine containing Mirvetuximab soravtansine for intravenous use, marketed by ImmunoGen, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store ELAHERE vials upright in a refrigerator at 2°C to 8°C (36°F to 46°F)…
Key facts
- Active ingredient (INN)
- Mirvetuximab soravtansine
- Brand
- Elahere
- Strength
- 100 mg/20 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 20 mL
- Marketing authorisation holder
- ImmunoGen
- Manufacturer
- ImmunoGen
- Origin register
- US FDA, United States
- Storage
- Store ELAHERE vials upright in a refrigerator at 2°C to 8°C (36°F to 46°F) until the time of preparation in the original carton to protect from light. Do not freeze or shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FX26 Mirvetuximab soravtansine
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 14 November 2022
- Identifiers
- RxCUI 2621553, 2621559DailyMed set ID 00c424b5-6ccd-48ab-9e88-1986451120e2NDC 72903-853Application BLA761310
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 20 mL in 1 vial, single-use | 72903-853-01 | ImmunoGen | 14 November 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Mirvetuximab soravtansine is a prescription medicine indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer,, among other approved uses. MedsAcross supplies Mirvetuximab soravtansine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Mirvetuximab soravtansineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ELAHERE prescribing information (ImmunoGen) · U.S. National Library of Medicine, DailyMed
- Elahere: European public assessment report (EPAR) · European Medicines Agency
Need Elahere 100 mg/20 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.